Good MorningEquities started the week on positive footing with the S&P 500 index moving up slightly to set a new all-time high. Monday’s action marks the 12th positive close in three weeks for the index and could easily lead to another string of new highs. The move is driven by corporate earnings that have come in better than expected despite strong headwinds within the economy. This week, traders will on alert for reports from another 167 S&P 500 companies marking the busiest week of the reporting season. By the end of this week, nearly 90% of the index will have reported results for the season.
Also on tap this week, a key meeting of the FOMC and the monthly NFP report. The FOMC is expected to begin tapering or explain why they are waiting while the NFP is expected to be a tepid 450,000. After last months’ decline in total unemployment claims, the NFP figure should run well into the millions.
Featured: Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom (Ad) 
|
Markets | | | As we learned with Starbucks’ (NASDAQ:SBUX) recent quarterly report, sometimes even record sales aren’t enough. The popular coffee shop operator delivered its best fourth-quarter result ever last week, Read the Full Story |
|
From Our Partners | | We’ve got seven great summertime plays for you. These stocks are in a prime position to reward your portfolio… especially if you take action before summer is in full swing!
They cover summer-centric industries such as solar, home improvement, entertainment, travel, and more.
To keep you motivated during these summer months, we’d like to give you a FREE report revealing these companies – 7 Best Stocks to Own in Summer 2025. | | Get Your Copy of "7 Best Stocks to Own in Summer 2025" Here. |
|
Stocks | | | Shares of monday.com (NASDAQ: MNDY) are consolidating above key moving averages below a September 2 high of $425.84.
It’s one of several enterprise-focused software applications showing technical strength right now.
Rivals including Atlassian (NASDAQ: TEAM) and Asana (NYSE: ASAN)... Read the Full Story |
|
Politics | | | Asian shares were mixed Tuesday amid cautious trading ahead of a policy meeting by the U.S. Federal Reserve.
Japan's benchmark Nikkei 225 lost 0.4% to finish at 29,520.90. Australia's S&P/ASX 200 slipped 0.6% to 7,324.30. South Korea's Kospi surged 1.1% to 3,012.63. Hong Kong's H... Read the Full Story |
|
From Our Partners | | I made a mistake.
A mistake I feel very foolish about.
After speaking with Donald Trump and some of his advisors, I believed him.
I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years.
But I was wrong. | | Let me show you exactly what we’re doing to prepare. |
|
Markets | | | Small-cap Brigham Minerals (NYSE: MNRL) is trading in new high ground ahead of the company's third-quarter earnings report after the market close on Wednesday. The company will host its earnings conference call on Thursday at noon Eastern. Read the Full Story |
|
Politics | | | Global shares were mixed Tuesday amid cautious trading ahead of a policy meeting by the U.S. Federal Reserve.
France's CAC 40 rose 0.2% to 6,904.57, while Germany's DAX gained 0.2% to 15,837.55. Britain's FTSE 100 dipped 0.5% to 7,254.78. The future for the Dow industrials inched les... Read the Full Story |
|
From Our Partners | | Tesla's About to Prove Everyone Wrong... Again
Back in 2018, when Jeff Brown told everyone to buy Tesla…
The "experts" said Elon was finished and Tesla was headed for bankruptcy.
Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | | Click here to see why Tesla's about to prove everyone wrong... again. |
|
Politics | | | A California judge has ruled for top drug manufacturers as local governments seek billions of dollars to cover their costs from the nation’s opioid epidemic.
Orange County Superior Court Judge Peter Wilson issued a tentative ruling on Monday that said the governments hadn’t proven the... Read the Full Story |
|
Politics | | | A California judge has ruled for top drug manufacturers as local governments seek billions of dollars to cover their costs from the nation’s opioid epidemic.
Orange County Superior Court Judge Peter Wilson issued a tentative ruling on Monday that said the governments hadn’t proven the... Read the Full Story |
|
Politics | | | A California judge has ruled for top drug manufacturers as local governments seek billions of dollars to cover their costs from the nation’s opioid epidemic.
Orange County Superior Court Judge Peter Wilson issued a tentative ruling on Monday that said the governments hadn’t proven the... Read the Full Story |
|
Markets | | | Hydrogen fuel cell technology provider Plug Power (NASDAQ: PLUG) stock is getting a second wind as it rises after losing more than (-60%) from its 2021 highs of $75.49. The hydrogen fuel cell pioneer’s energy technology is being validated through partnerships with many large companies includin... Read the Full Story |
|
Markets | | | The Clorox Company (NYSE: CLX) is a poster child for both the pandemic and post-pandemic worlds. The company saw a 500% increase in demand for its products that outpaced expectations during both the spike and decline that has shares trading at their lowest levels in nearly a year. Read the Full Story |
|
The Early Bird Stock Of The Day Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. | | View Today's Stock Pick |
|
